Clinical Trials Logo

Filter by:
NCT ID: NCT03699839 Completed - Influenza Clinical Trials

Reducing the Burden of Influenza After Solid-Organ Transplantation

STOP-FLU
Start date: October 26, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

Influenza is associated with significant morbidity and mortality in solid-organ transplant (SOT) recipients and it is mainly prevented by seasonal influenza vaccination. Unfortunately, the immunogenicity of standard influenza vaccine is suboptimal in this population. Vaccination with a high-dose (HD) influenza vaccine or an MF59-adjuvanted (MF59a) vaccine have significantly reduced the incidence of influenza and increased the immunogenicity of influenza vaccine in the elderly. The investigators will compare the immunogenicity and efficacy of two new vaccination strategies, consisting in vaccination with a HD influenza vaccine or an MF59a influenza vaccine, to the standard-dose non-adjuvanted vaccination (standard of care) in a population of SOT recipients.

NCT ID: NCT03699436 Completed - Raynaud Phenomenon Clinical Trials

Effectiveness of Electric Stimulation Therapy in Raynaud's Phenomenon

Start date: October 1, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to analyze the effects of an intervention with galvanic electrical current on the number of attacks , temperature, pain, peripheral blow flow and upper limb functionality in patients with Raynaud's Phenomenon in comparison to a control group that will maintain their habitual treatment.

NCT ID: NCT03699254 Completed - Clinical trials for Cytomegalovirus Infections

Clinical Trial of Efficacy and Safety of the Combination of Reduced Duration Prophylaxis Followed by Immuno-guided Prophylaxis in Lung Transplant Recipients.

CYTOCOR
Start date: April 5, 2019
Phase: Phase 3
Study type: Interventional

To assess the efficacy of reduced duration prophylaxis followed by immuno-guided prophylaxis to prevent cytomegalovirus disease.

NCT ID: NCT03699111 Completed - Clinical trials for Advanced Colorectal Cancer

Identification of New Patient Stratification Tools in MSS RAS mt mCRC

COLOSSUS
Start date: September 19, 2018
Phase:
Study type: Observational

This is a translational, multicentre and multinational study. The aim of this study is to identify new patient stratification tools in microsatellite stable RAS mutant metastatic Colorectal Cancer

NCT ID: NCT03698110 Completed - Parenting Clinical Trials

Programa PUEDES Infancia

PUEDES
Start date: March 30, 2017
Phase: N/A
Study type: Interventional

The purpose of this study was to evaluate whether an intervention directed at promoting parental self-efficacy and skills, based on a positive parenting framework, improves parental competences and healthy practices in families with children aged 2 to 5 years old.

NCT ID: NCT03697109 Completed - Cushing Syndrome Clinical Trials

A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome

GRACE
Start date: November 15, 2018
Phase: Phase 3
Study type: Interventional

This is a Phase 3, double-blind, placebo-controlled, randomized-withdrawal study to assess the efficacy, safety and pharmacokinetics (PK) of relacorilant in patients with endogenous Cushing syndrome and concurrent type 2 diabetes mellitus/impaired glucose tolerance and/or uncontrolled hypertension

NCT ID: NCT03695380 Completed - OVARIAN CANCER Clinical Trials

A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer

Start date: January 9, 2019
Phase: Phase 1
Study type: Interventional

The study will include a safety run-in phase (Stage 1) and a randomization phase (Stage 2). The purpose of Stage 1 is to evaluate the safety of cobimetinib when administered in combination with niraparib (Cohort 1) and cobimetinib with niraparib plus atezolizumab (Cohort 2). Stage 1 will enable patient enrollment in the randomized phase of the study (Stage 2) with both regimens at the recommended dose levels from Stage 1. Stage 2 is a randomized, dose-expansion phase, evaluating clinical outcomes in patients with advanced platinum-sensitive ovarian cancer. All patients will continue to receive study treatment until disease progression (according to "Response Evaluation Criteria in Solid Tumors" (RECIST), Version 1.1, unacceptable toxicity, death, or patient or investigator decision to withdraw, whichever occurs first.

NCT ID: NCT03695185 Completed - Clinical trials for Ulcerative Colitis (UC)

A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy

Start date: March 26, 2019
Phase: Phase 2
Study type: Interventional

Study M15-722 is a Phase 2a study to investigate the efficacy and safety of Ravagalimab (ABBV-323) in participants with moderate to severe UC who failed prior therapy.

NCT ID: NCT03694522 Completed - Gastric Cancer Clinical Trials

A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer

FIGHT
Start date: September 14, 2018
Phase: Phase 2
Study type: Interventional

The main objective of the Phase 2 part of the study is to evaluate the efficacy of bemarituzumab (FPA144), a targeted antibody, in combination with modified FOLFOX6 compared to placebo in combination with modified FOLFOX6 in participants with advanced gastrointestinal cancer.

NCT ID: NCT03693508 Completed - HIV Infections Clinical Trials

A Clinical Trial to Evaluate the Efficacy and Safety of Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Alafenamide as a First-line Treatment in Naïve Patients With HIV-1 Infection With Severe Immunosuppression

GENIS
Start date: April 13, 2018
Phase: Phase 4
Study type: Interventional

Phase IV, open, multicentre and single-arm study. 50 HIV infection naive patients with severe immunosuppression will be recruited to evaluate the efficacy and safety of elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide as a first-line treatment.